Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.46 |
| ▸ | USP10 | Q14694 | 1/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.38 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662268 | 1.00 | ATM (0.58) | ATMTDP1PDE7AUSP10USP7 | |
| SCHEMBL3874156 | 0.85 | PDE7A (0.58) | ATMTDP1PDE7AUSP10USP7 | |
| SCHEMBL20150186 | 0.81 | TSHR (0.64) | TDP1TSHRCYP3A4IDO1ALDH1A1 | |
| SCHEMBL2061399 | 0.81 | ATM (0.58) | ATMTDP1PDE7AUSP10USP7 | |
| SCHEMBL5423544 | 0.78 | PDE7A (0.42) | ATMTDP1PDE7ATSHRCYP3A4 | |
| SCHEMBL2935849 | 0.78 | BACE1 (0.45) | TSHRCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL29662266 | 0.78 | BACE1 (0.45) | TSHRCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL8446725 | 0.78 | TSHR (0.58) | TDP1PDE7ATSHRCYP3A4ALDH1A1 | |
| SCHEMBL2545546 | 0.78 | MAPK1 (0.58) | TDP1PDE7ATSHRALDH1A1MAPT | |
| SCHEMBL21445773 | 0.77 | ATM (0.53) | ATMTDP1PDE7AUSP10USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| CN-111217816-B | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2021013712-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2021-01-28 | — | — | WO | disclosed |
| CN-111217816-A | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2020-06-02 | — | — | CN | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| EP-2291377-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | ATM 4490/4885TDP1 616/4885PDE7A 164/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ATM 759/4885TDP1 330/4885PDE7A 3971/4885 |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | ATM 1764/4885TDP1 1251/4885PDE7A 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.